2. Antibody-drug Conjugate/ADC Related Protein Tyrosine Kinase/RTK Apoptosis Cell Cycle/DNA Damage Cytoskeleton Stem Cell/Wnt MAPK/ERK Pathway PI3K/Akt/mTOR
  3. Antibody-Drug Conjugates (ADCs) c-Kit Apoptosis Microtubule/Tubulin ERK Akt Caspase
  4. NN3201

NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research[1][2].

For research use only. We do not sell to patients.

NN3201

NN3201 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

NN3201 Related Antibodies

Top Publications Citing Use of Products

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research[1][2].

In Vitro

NN3201 (1 µg/mL, 1 h) exhibits dose-dependent binding to c-Kit-high and c-Kit-medium cell lines, which saturated at 315 pM, with no binding observed to c-Kit-low or negative cell lines[1].
NN3201 (1 µg/mL, 0.5-24 h) internalizes rapidly (within 30 minutes) and continuously in c-Kit-positive GIST-T1 cells, with the signal increasing for up to 24 hours, but its internalization was c-Kit-dependent[1].
NN3201 (3-7 days) demonstrates potent, c-Kit-dependent cytotoxicity mediated by its MMAE payload in a panel of positive cell lines, with GI50 values of 0.09 nM (GIST-T1), 0.69 nM (GIST-430), 0.12 nM (GIST-430/654), and 17.06 nM (NCI-H1048)[1].
NN3201 (0.01-1 µg/mL, 1 h) dose-dependently decreases the SCF-mediated phosphorylation on c-Kit (Y719, Y568/570), Erk1/2, and Akt (S473) in NCI-H1048 cells, while only partially suppressing phosphorylation (pY568/570 c-Kit and pErk1/2) in GIST-430/654 cells[1].
NN3201 (1 µg/mL, 1-3 days) induces c-Kit degradation and signaling inhibition through continuous internalization, which triggered apoptosis, demonstrated by the increase in cleaved caspase-3 and caspase-7[1].
NN3201 (5 µg/mL, 24-48 h) induces cell cycle arrest in the G2/M and sub-G1 phases, which is attributed to the microtubule-disrupting action of its released MMAE payload[1].
NN3201 (4 µg/mL, 7 days) triggers a potent bystander effect, mediated by free MMAE released from NN3201-treated GIST-430/654 cells, which killed neighboring MCF7-GFP⁺ cancer cells with negligible c-Kit expression[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

NN3201 Related Antibodies

Cell Viability Assay[1]

Cell Line: MCF7-GFP+ cells
Concentration: 4 μg/mL
Incubation Time: 7 days
Result: Exhibited negligible cytotoxicity (GI50 >20 µg/mL) against the c-Kit-negative MCF7-GFP⁺ cell line, consistent with its target-dependent mechanism and in sharp contrast to the potent activity of its free payload, MMAE (GI50 = 4.96 nM).

Cell Cycle Analysis[1]

Cell Line: GIST-430/654 and NCI-H1048 cells
Concentration: 1 μg/mL
Incubation Time: 24 and 48 h
Result: Induced substantial cell cycle arrest at the G2/M phase and increased the sub-G1 population in both cell lines.

Western Blot Analysis[1]

Cell Line: GIST-430/654 and MCI-H1048 cells
Concentration: 1 μg/mL
Incubation Time: 1, 2, and 3 days
Result: Induced a time-dependent degradation of c-Kit in both cell lines.
Increased levels of cleaved caspase-3 and caspase-7.
Eventually inhibited the c-Kit downstream signaling pathway by sustained internalization and degradation of the NN3201-c-Kit complex over 3 days.
In Vivo

NN3201 (0.5-10 mg/kg, i.v., Q10D x 3 or Q1W x 3) exhibits significant c-Kit-dependent anti-tumor efficacies in various GIST and SCLC tumor mice models[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with GIST-T1 cells[1]
Dosage: 0.5, 1.5 and 3.0 mg/kg
Administration: i.v., Q10D x 3
Result: Completely regressed tumor volume for up to 112 days at 1.5 and 3 mg/kg, with Imatinib (HY-15463) (100 mg/kg, p.o., Q1D x 30) only inhibited tumor progression during the treatment period.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: NOG mice (5-6 weeks old) subcutaneously injected with GIST-430/654 cells[1]
Dosage: 1, 3 and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Induced significant tumor shrinkage at 3 mg/kg and 5 mg/kg, and stably controlled until day 42 and 49, respectively.
Induced tumor growth inhibition (TGI) of 47.2 % on day 21 at 1 mg/kg, which was similar to that by 30 mg/kg of Sunitinib (HY-10255A) (30 mg/kg, p.o., Q1D x 21; TGI of 45.2 % on day 21).
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female NOD/SCID mice subcutaneously implanted with GS5108 tumors[1]
Dosage: 3, 5 and 10 mg/kg
Administration: i.v., Q1W x 3
Result: Induced durable tumor stasis at 10 mg/kg, which was followed by significant tumor regression for up to 60 days.
Demonstrated superior in vivo efficacy over all standard-of-care (SoC) treatments in the 3rd line GIST models.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H526 cells[1]
Dosage: 1, 1.5, 2, 2.5 and 3 mg/kg
Administration: i.v., Q1W x 3
Result: Induced complete regression of the tumor with no regrowth after 70 and 84 days at 2.5 and 3 mg/kg.
Exhibited 84.9 % of TGI compared to the vehicle control on day 17 at 2 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H1048 cells[1]
Dosage: 1, 3, and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Showed TGI of 95.1 % on day 21 at 1 mg/kg, better than the combination of Carboplatin (HY-17393) (60 mg/kg, i.p., day 0 and 10) and Etoposide (HY-13629) (3 mg/kg. i.p., day 0~4 and 10~14; TGI = 70.51 % on day 21).
Induced complete tumor remission for up to 35 days and 56 days at 3 mg/kg and 5 mg/kg, respectively.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with NCI-H1048 cells[1]
Dosage: 5 mg/kg
Administration: i.v., Q1W x 3
Result: Was able to reduce the tumor volume to below baseline, whereas neither Topotecan (HY-13768) (0.83 mg/kg, i.p., BIW x 3) nor Irinotecan (HY-16562) (33 mg/kg, i.v., Q1W x 3) could achieve this.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female C.B-17 SCID mice (5-6 weeks old) subcutaneously injected with SHP-77 cells[1]
Dosage: 1, 3, and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Exhibited no in vivo potency in SHP-77 xenografts, where c-Kit expression is negligible, confirming its c-Kit driven property.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female Hsd: Athymic Nude-Foxn1nu mice subcutaneously implanted with CTG-1252 tumors[1]
Dosage: 1, 3, and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Dose-dependently inhibited tumor growth.
Achieved 70 days of complete regression at 5 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
Animal Model: Female Hsd: Athymic Nude-Foxn1nu mice subcutaneously implanted with CTG-2093 tumors[1]
Dosage: 1, 3, and 5 mg/kg
Administration: i.v., Q1W x 3
Result: Induced tumor stasis until day 27 with TGI of 84.8 % at 5 mg/kg.
Induced no body weight loss but rather an increase as tumor size enlarges.
SMILES

[NN3201]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

NN3201 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NN3201NN 3201NN-3201Antibody-Drug Conjugates (ADCs)c-KitApoptosisMicrotubule/TubulinERKAktCaspaseAntibody-Drug ConjugatesSCFRCD117Extracellular signal regulated kinasesPKBProtein kinase BADCc-Kit-positive tumorsSCF-driven signalingapoptosisFcγRSCLCGISTNCI-H1048MCF7-GFP?GIST-430/654AMLInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
NN3201
Cat. No.:
HY-177578
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.